FDA Rejects Disc Medicine's Porphyria Drug Over Uncertain Biomarker Benefit
TL;DR Summary
The FDA rejected Disc Medicine's bitopertin for porphyria, citing uncertainties that the biomarker used as the efficacy endpoint may not translate to real patient benefit, marking the first setback for a drug in Commissioner Makary's fast-track review program and sending Disc's shares lower.
- FDA rejects rare disease therapy from Disc Medicine, early recipient of commissioner’s voucher statnews.com
- FDA rejects Disc's rare disease drug despite commissioner's voucher Fierce Biotech
- Drug For Rare Genetic Disorder Goes From FDA Priority to Reject in Four Months Bloomberg.com
- Disc Medicine (IRON) Shares Plunge by 39% to $43.99 GuruFocus
- FDA issues complete response letter for Disc Medicine’s EPP drug Investing.com Nigeria
Reading Insights
Total Reads
0
Unique Readers
10
Time Saved
2 min
vs 3 min read
Condensed
90%
423 → 43 words
Want the full story? Read the original article
Read on statnews.com